Chapter 51 : Immune Responses to Polysaccharide and Conjugate Vaccines

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Immune Responses to Polysaccharide and Conjugate Vaccines, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap51-1.gif /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap51-2.gif


Estimation of antibody concentrations and measurements of functional antibody are critical to one's understanding of polysaccharide (PS)-induced immunity. Information on quantitative immunoassays for anti-PS antibodies is presented in this chapter. In an assessment of naturally occurring levels of antibody to encapsulated bacteria and evaluation of the immune response to PS or conjugate vaccines, one should consider both antibody quantitation and measures of biological (functional) activity. Quantitation of anti-PS antibody is important, because as the type-specific antibody concentration increases, the risk of invasive disease on a population basis due to that bacterial strain decreases. The enzyme-linked immunosorbent assay (ELISA) is now the most commonly used method for quantitation of antibody concentration. The presence or induction of bactericidal antibody is predictive of protection against meningococcal disease. The major problem that presents is its ability to cause outbreaks and epidemics. The pneumococcal PSs are poorly immunogenic and fail to induce protective antibody levels in children <2 years of age. For this reason conjugate vaccines were developed against the 7 to 11 most common pediatric pneumococcal types. In Nepal, where the attack rate in individuals 5 to 44 years of age was 16.2/1,000, the Vi PS vaccine given as a single 25-μg dose had an efficacy of 75% measured 17 months after vaccination. This study clearly showed that serum antibodies to the Vi PS were sufficient to protect against typhoid fever.

Citation: Frasch C. 2006. Immune Responses to Polysaccharide and Conjugate Vaccines, p 434-443. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch51

Key Concept Ranking

Pneumococcal Conjugate Vaccine
Meningococcal Conjugate Vaccine
Bacterial Vaccines
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Age-related maturation in antibody response to PSs. Antibody response to four serotypes upon immunization with the pneumococcal PS vaccine in children from 1 to 15 years of age was measured.

Citation: Frasch C. 2006. Immune Responses to Polysaccharide and Conjugate Vaccines, p 434-443. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch51
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Acharya, I. L.,, C. U. Lowe,, R. Thapa,, V. L. Gurubacharya,, M. B. Shrestha,, M. Cadoz,, D. Schulz,, J. Armand,, D. A. Bryla,, B. Trollfors, et al. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N. Engl. J. Med. 317:11011104.
2. Ambrosino, D. M.,, G. Schiffman,, E. C. Gotschlich,, P. H. Schur,, G. A. Rosenberg,, G. G. DeLange,, E. van Loghem, and , G. R. Siber. 1985. Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J. Clin. Investig. 75:19351942.
3. Arakere, G., and , C. E. Frasch. 1991. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect. Immun. 59:43494356.
4. Barrett, D. J.,, A. J. Ammann,, S. Stenmark, and , D. W. Wara. 1980. Immunoglobulin G and M antibodies to pneumococcal polysaccharides detected by enzyme-linked immunosorbent assay. Infect. Immun. 27:411417.
5. Baxendale, H. E.,, Z. Davis,, H. N. White,, M. B. Spellerberg,, F. K. Stevenson, and , D. Goldblatt. 2000. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur. J. Immunol. 30:12141223.
6. Berry, D. S.,, F. Lynn,, C. H. Lee,, C. E. Frasch, and , M. C. Bash. 2002. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. 70:37073713.
7. Bhushan, R.,, B. F. Anthony, and , C. E. Frasch. 1998. Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent. Infect. Immun. 66:58485853.
8. Black, S.,, H. Shinefield,, B. Fireman,, E. Lewis,, P. Ray,, J. R. Hansen,, L. Elvin,, K. M. Ensor,, J. Hackell,, G. Siber,, F. Malinoski,, D. Madore,, I. Chang,, R. Kohberger,, W. Watson,, R. Austrian,, K. Edwards, and Northern California Kaiser Permanente Vaccine Study Center Group. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187195.
9. Booy, R., and , E. R., Moxon. 1993. Haemophilus influenzae type b. Arch. Dis. Child. 68:440441.
10. Borrow, R.,, N. Andrews,, D. Goldblatt, and , E. Miller. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:15681573.
11. Bramley, J. C.,, T. Hall,, A. Finn,, R. B. Buttery,, D. Elliman,, S. Lockhart,, R. Borrow, and , I. G. Jones. 2001. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 19:29242931.
12. Burian, V.,, E. Gotschlich,, P. Kuzemenska, and , E. Svandova. 1977. Naturally occurring antibodies to Neisseria meningitidis. Bull. W.H.O. 55:653657.
13. Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 46:124.
14. Chippaux, J. R.,, H. Debois, and , R. Saliou. 2002. A critical review of control strategies against meningococcal meningitis epidemics in sub-Saharan African countries. Infection 30:216224.
15. Concepcion, N., and , C. E. Frasch. 1998. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin. Diagn. Lab. Immunol. 5:199204.
16. Concepcion, N. F., and , C. E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266272.
17. Deveikis, A.,, J. Ward, and , K. S. Kim. 1988. Functional activities of human antibody induced by the capsular polysaccharide or polysaccharide-protein conjugate vaccines against Haemophilus influenzae type b. Vaccine 6:1418.
18. Dintzis, R. Z. 1994. Structure/function relationships in vaccines, p. 111127. In R. W. Ellis and , D. M. Granoff (ed.), Development and Clinical Uses of Haemophilus b Conjugate Vaccines. Marcel Dekker, New York, N.Y.
19. Douglas, R. M.,, J. C. Paton,, S. J. Duncan, and , D. J. Hansman. 1983. Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 148:131137.
20. Edelman, R., and , M. M. Levine. 1986. Summary of an international workshop on typhoid fever. Rev. Infect. Dis. 8:329349.
21. Elie, C. M.,, P. K. Holder,, S. Romero-Steiner, and , G. M. Carlone. 2002. Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y, and W-135 meningococcal standard reference serum CDC1992. Clin. Diagn. Lab. Immunol. 9:725726.
22. Esposito, S., and , N. Principi. 2003. Effect of conjugate pneumococcal vaccine on recurrent acute otitis media. Lancet 362:10801081.
23. Finn, A.,, Q. B. Zhang,, L. Seymour,, C. Fasching,, E. Pettitt, and , E. N. Janoff. 2002. Induction of functional secretory IgA responses in breast milk by pneumococcal capsular polysaccharides. J. Infect. Dis. 186:14221429.
24. Frasch, C. E. 1995. Meningococcal vaccines: past, present and future, p. 245283. In K. Cartwright (ed.), Meningococcal Disease. Wiley, New York, N.Y.
25. Glode, M. P.,, E. B. Lewin,, A. Sutton,, C. T. Le,, E. C. Gotschlich, and , J. B. Robbins. 1979. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J. Infect. Dis. 139:5259.
26. Gold, R. 1979. Immunogenicity of meningococcal polysaccharides in man, p. 121150. In J. A. Rudbach and , P. J. Baker (ed.), Immunology of Bacterial Polysaccharides. Elsevier, Amsterdam, The Netherlands.
27. Goldschneider, I.,, E. C. Gotschlich, and , M. S. Artenstein. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:13271348.
28. Granoff, D. M.,, R. K. Gupta,, R. B. Belshe, and , E. L. Anderson. 1998. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J. Infect. Dis. 178:870874.
29. Granoff, D. M.,, S. J. Holmes,, M. T. Osterholm,, J. E. McHugh,, A. H. Lucas,, E. L. Anderson,, R. B. Belshe,, J. L. Jacobs,, F. Medley, and , T. V. Murphy. 1993. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 168:663671.
30. Janoff, E. N.,, C. Fasching,, J. M. Orenstein,, J. B. Rubins,, N. L. Opstad, and , A. P. Dalmasso. 1999. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J. Clin. Investig. 104:11391147.
31. Jodar, L.,, J. Butler,, G. Carlone,, R. Dagan,, D. Goldblatt,, H. Kaeyhty,, K. Klugman,, B. Plikaytis,, G. Siber,, R. Kohberger,, I. Chang, and , T. Cherian. 2003. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21:32653272.
32. Johnson R. B., Jr. 1981. The host response to invasion by Streptococcus pneumoniae: protection and the pathogenesis of tissue damage. Rev. Infect. Dis. 3:282288.
33. Keitel, W. A.,, N. L. Bond,, J. M. Zahradnik,, T. A. Cramton, and , J. B. Robbins. 1994. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12:195199.
34. Klugman, K. P.,, I. T. Gilbertson,, H. J. Koornhof,, J. B. Robbins,, R. Schneerson,, D. Schulz,, M. Cadoz, and , J. Armand. 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet ii:11651169.
35. Klugman, K. P.,, H. J. Koornhof,, J. B. Robbins, and , N. N. Le Cam. 1996. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14:435438.
36. Kossaczka, Z.,, F. Y. Lin,, V. A. Ho,, N. T. Thuy,, P. Van Bay,, T. C. Thanh,, H. B. Khiem,, D. D. Trach,, A. Karpas,, S. Hunt,, D. A. Bryla,, R. Schneerson,, J. B. Robbins, and , S. C. Szu. 1999. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 67:58065810.
37. Law, B. J.,, T. Rosenberg,, N. E. MacDonald,, F. E. Ashton,, J. C. Huang,, W. J. King,, W. J. Ferris, and , G. J. Gray. 1998. Age-related immunogenicity of meningococcal polysaccharide vaccine in Aboriginal children and adolescents living in a Northern Manitoba reserve community. Pediatr. Infect. Dis. J. 17:860864.
38. Leinonen, M.,, A. Sakkinen,, R. Kalliokoski,, J. Luotonen,, M. Timonen, and , P. H. Makela. 1986. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr. Infect. Dis. 5:3944.
39. Lennon, D.,, B. Gellin,, D. Hood,, L. Voss,, H. Heffernan, and , S. Thakur. 1992. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr. Infect. Dis.J. 11:617623.
40. Levine, M. M.,, C. Ferreccio,, R. E. Black, and , R. Germanier. 1987. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet i:10491052.
41. Lin, F. Y.,, V. A. Ho,, H. B. Khiem,, D. D. Trach,, P. V. Bay,, T. C. Thanh,, Z. Kossaczka,, D. A. Bryla,, J. Shiloach,, J. B. Robbins,, R. Schneerson, and , S. C. Szu. 2001. The efficacy of a Salmonella typhi Vi conjugate vaccine in two- to five-year-old children. N. Engl. J. Med. 344:12631269.
42. Lottenbach, K. R.,, C. M. Mink,, S. J. Barenkamp,, E. L. Anderson,, S. M. Homan, and , D. C. Powers. 1999. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect. Immun. 67:49354938.
43. MacDonald, N. E.,, S. A. Halperin,, B. J. Law,, L. E. Danzig, and , D. M. Granoff. 2000. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA 283:18261827.
44. MacDonald, N. E.,, S. A. Halperin,, B. J. Law,, B. Forrest,, L. E. Danzig, and , D. M. Granoff. 1998. Induction of immunologic memory by conjugated vs. plain meningococcal C polysaccharide vaccine in toddlers—a randomized controlled trial. JAMA 280:16851689.
45. MacLeod, C. M.,, R. G. Hodges,, M. Heidelberger, and , W. G. Bernhard. 1945. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82:445465.
46. Madore, D. V.,, P. Anderson,, B. D. Baxter,, G. M. Carlone,, K. M. Edwards,, R. G. Hamilton,, P. Holder,, H. Kayhty,, D. C. Phipps,, C. C. Peeters,, R. Schneerson,, G. R. Siber,, J. I. Ward, and , C. E. Frasch. 1996. Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 3:8488.
47. Madore, D. V.,, C. L. Johnson,, D. C. Phipps,,Pennridge Pediatric Associates, M. G. Myers,, R. Eby, and , D. H. Smith. 1990. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months. Pediatrics 86:527534.
48. Miller, E.,, D. Salisbury, and , M. Ramsay. 2001. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl.1):S58S67.
49. Reference deleted.
50. Ostroff, S. M. 1999. Continuing challenge of pneumococcal disease. Lancet 353:12011202.
51. Paton, J. C.,, I. R. Toogood,, R. A. Cockington, and , D. Hansman. 1986. Antibody response to pneumococcal vaccine in children aged 5 to 15 years. Am. J. Dis. Child. 140:135138.
52. Peltola, H.,, H. Kayhty,, M. Virtanen, and , P. H. Makela. 1984. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N. Engl. J. Med. 310:15611566.
53. Phipps, D. C.,, J. West,, R. Eby,, M. Koster,, D. V. Madore, and , S. A. Quataert. 1990. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J. Immunol. Methods 135:121128.
54. Plotkin, S. A., and , N. Bouveret-Le Cam. 1995. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch. Intern. Med. 155:22932299.
55. Quataert, S. A.,, C. S. Kirch,, L. J. Wiedl,, D. C. Phipps,, S. Strohmeyer,, C. O. Cimino,, J. Skuse, and , D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590597.
56. Robbins, J. B.,, J. C. Parke,, R. Schneerson, and , J. K. Whisnant. 1973. Quantitative measurement of “natural” and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr. Res. 7:103110.
57. Robbins, J. D., and , J. B. Robbins. 1984. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J. Infect. Dis. 150:436449.
58. Roberts, R. B. 1970. The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man. J. Exp. Med. 131:499513.
59. Romero-Steiner, S.,, D. M. Musher,, M. S. Cetron,, L. B. Pais,, J. E. Groover,, A. E. Fiore,, B. D. Plikaytis, and , G. M. Carlone. 1999. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29:281288.
60. Schlesinger, Y.,, D. M. Granoff, and The Vaccine Study Group. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 267:14891494.
61. Shapiro, E. D., and , J. I. Ward. 1991. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol. Rev. 13:113142.
62. Siber, G. R.,, D. M. Ambrosino,, J. McIver,, T. J. Ervin,, G. Schiffman,, S. Sallan, and , G. F. Grady. 1984. Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis. Infect. Immun. 45:248254.
63. Skevakis, L.,, C. E. Frasch,, J. M. Zahradnik, and , R. Dolin. 1984. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis. J. Infect. Dis. 149:387396.
64. Soininen, A.,, H. Pursiainen,, T Kilpi, and , H. Kaeyhty. 2001. Natural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young children. J. Infect. Dis. 184:569576.
65. Stein, K. E. 1992. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165:S49S52.
66. Szu, S. C.,, X. R. Li,, A. L. Stone, and , J. B. Robbins. 1991. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 59:45554561.
67. Trotter, C.,, R. Borrow,, N. Andrews, and , E. Miller. 2003. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 21:10941098.
68. Usinger, W. R., and , A. H. Lucas. 1999. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:23662370.
69. Van Parijs, B. A. 2004. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 22:13621371.
70. Vitharsson, G.,, I. Jonsdottir,, S. Jonsson, and , H. Valdimarsson. 1994. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 170:592599.
71. Zepp, F.,, H. J. Schmitt,, A. Kaufhold,, A. Schuind,, M. Knuf,, P. Habermehl,, C. Meyer,, H. Bogaerts,, M. Slaoui, and , R. Clemens. 1997. Evidence for induction of polysaccharide specific B-cell memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur. J. Pediatr. 156:1824.
72. Zysk, G.,, G. Bethe,, R. Nau,, D. Koch,, V. C. D. H. Von Bassewitz,, H. P. Heinz, and , R. R. Reinert. 2003. Immune response to capsular polysaccharide and surface proteins of Streptococcus pneumoniae in patients with invasive pneumococcal disease. J. Infect. Dis. 187:330333.


Generic image for table

Bacterial PS vaccines licensed in the United States

Citation: Frasch C. 2006. Immune Responses to Polysaccharide and Conjugate Vaccines, p 434-443. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch51
Generic image for table

Bacterial PS-protein conjugate vaccines licensed in the United States

Citation: Frasch C. 2006. Immune Responses to Polysaccharide and Conjugate Vaccines, p 434-443. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch51
Generic image for table

Human reference sera for ELISA

Citation: Frasch C. 2006. Immune Responses to Polysaccharide and Conjugate Vaccines, p 434-443. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch51

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error